Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
By binding to BCL-2 protein, venetoclax inhibits the obstruction of apoptosis of tumor cells and effectively kills cancer cells. Venetoclax was approved by the NMPA in 2020 for the···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：250
Venetoclax is a small molecule drug approved in combination with azacitidine for the treatment of acute myeloid leukemia. Initially indicated as chronic lymphocytic leukemia, it ha···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：238
Venetoclax is an oral targeted drug that can effectively inhibit the anti-apoptotic function of BCL-2 protein and restore the normal death of cancer cells. The drug is usually used···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：300
Venetoclax is a targeted drug used in the treatment of a variety of hematologic malignancies, mainly by blocking the activity of BCL-2 protein to promote apoptosis of tumor cells. ···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：254
Venetoclax is the only approved selective inhibitor of Bcl-2 in the world. By binding Bcl-2 protein with high affinity, Bax/Bak-dependent apoptosis is induced and platelet damage i···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：265
As a potent and selective oral inhibitor targeting FGFR subtypes 1/2/3, Pemigatinib provides a new treatment option for cholangiocarcinoma patients.What is the dosage of Pemigatini···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：180
Pemigatinib, brand name Damitan, is a potent and selective oral inhibitor against FGFR subtypes 1/2/3.How to use PemigatinibPemigatinibtablets should be swallowed whole, not chewed···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：172
Pemigatinibis a small molecule kinase inhibitor targeting the fibroblast growth factor receptor (FGFR), primarily for the treatment of advanced or metastatic cholangiocarcinoma cau···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：239
Pemigatinib is indicated for adult patients with advanced, metastatic, or unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement confirmed by testing.What are the suita···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：250
Pemigatinib is an innovative targeted therapy that provides a new treatment option for patients with FGFR2 fusion or rearranged cholangiocarcinoma.What diseases is Pemigatinib suit···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：281
Pemigatinibis mainly used to treat specific diseases such as advanced or metastatic cholangiocarcinoma caused by FGFR2 fusion or rearrangement.What are the indications for Pemigati···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：271
Pemigatinib is used in adults to treat bile duct cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery. Pemigatinib is usually given afte···【more】
Article source：Captain MedicineRelease date：2024-08-13Recommended：235
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
